Compare IBEX & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | SCTX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.0M | 536.5M |
| IPO Year | 2017 | 2026 |
| Metric | IBEX | SCTX |
|---|---|---|
| Price | $40.40 | $34.66 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 127.1K | ★ 209.3K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.63 | N/A |
| EPS | ★ 3.13 | N/A |
| Revenue | ★ $644,076,000.00 | N/A |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $13.07 | ★ N/A |
| Revenue Growth | ★ 15.37 | N/A |
| 52 Week Low | $25.94 | $17.31 |
| 52 Week High | $42.29 | $39.60 |
| Indicator | IBEX | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 61.07 |
| Support Level | $36.51 | $27.41 |
| Resistance Level | N/A | $39.60 |
| Average True Range (ATR) | 1.85 | 3.13 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 81.74 | 83.84 |
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.